Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
NCT01763190
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Impairment
Interventions
DRUG:
SAR302503
Sponsor
Bristol-Myers Squibb